Results 151 to 160 of about 34,607 (204)

Footprints of innate immune activity during HIV-1 reservoir cell evolution in early-treated infection. [PDF]

J Exp Med
Sun W, Gao C, Gladkov GT, Roseto I, Carrere L, Parsons EM, Gasca-Capote C, Frater J, Fidler S, Yu XG, Lichterfeld M, RIVER Trial Study Group.   +11 more
europepmc   +1 more source

Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 Clade C infection. [PDF]

Elife
Reddy K, Lee GQ, Reddy N, Chikowore TJB, Baisley K, Dong KL, Walker BD, Yu XG, Lichterfeld M, Ndung'u T.   +9 more
europepmc   +1 more source

Profound reduction of HIV-1 reservoir cells over 3 decades of antiretroviral therapy started in early infancy. [PDF]

JCI Insight
Vela LC, Carrere L, Naasz C, Kalavacherla S, Tan TS, de Armas L, Gao C, Yu XG, Pahwa SG, Luzuriaga K, Lichterfeld M.   +10 more
europepmc   +1 more source

Proliferation of HIV-1 reservoir cells: The delusion of infinite growth. [PDF]

J Exp Med
Lancien M, Lichterfeld M.
europepmc   +1 more source

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure. [PDF]

Nat Rev Microbiol
Armani-Tourret M, Bone B, Tan TS, Sun W, Bellefroid M, Struyve T, Louella M, Yu XG, Lichterfeld M.   +8 more
europepmc   +1 more source

The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers. [PDF]

J Clin Invest
Gasca-Capote C, Lian X, Gao C, Roseto IC, Jiménez-León MR, Gladkov G, Camacho-Sojo MI, Pérez-Gómez A, Gallego I, Lopez-Cortes LE, Bachiller S, Vitalle J, Rafii-El-Idrissi Benhnia M, Ostos FJ, Collado-Romacho AR, Santos J, Palacios R, Gomez-Ayerbe C, Muñoz-Medina L, Ruiz-Sancho A, Frias M, Rivero-Juarez A, Roca-Oporto C, Hidalgo-Tenorio C, Rull A, Olalla J, Lopez-Ruz MA, Vidal F, Viladés C, Mastrangelo A, Cavassini M, Espinosa N, Perreau M, Peraire J, Rivero A, López-Cortes LF, Lichterfeld M, Yu XG, Ruiz-Mateos E.   +38 more
europepmc   +1 more source

Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells. [PDF]

Nat Immunol
Board NL, Yuan Z, Wu F, Moskovljevic M, Ravi M, Sengupta S, Mun SS, Simonetti FR, Lai J, Tebas P, Lynn K, Hoh R, Deeks SG, Siliciano JD, Montaner LJ, Siliciano RF.   +15 more
europepmc   +1 more source

Long-term effects on immunological, inflammatory markers, and HIV-1 reservoir after switching to a two-drug versus maintaining a three-drug regimen based on integrase inhibitors. [PDF]

Front Immunol
Saborido-Alconchel A, Serna-Gallego A, Trujillo-Rodriguez M, Muñoz-Muela E, Álvarez-Ríos AI, Lozano C, Llaves-Flores S, Espinosa N, Roca-Oporto C, Herrero M, Sotomayor C, Gutierrez-Valencia A, Lopez-Cortes LF.   +12 more
europepmc   +1 more source

HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. [PDF]

Lancet HIV
Persaud D, Bryson Y, Nelson BS, Tierney C, Cotton MF, Coletti A, Jao J, Spector SA, Mirochnick M, Capparelli EV, Costello D, Szewczyk J, Nicodimus N, Stranix-Chibanda L, Kekitiinwa AR, Korutaro V, Reding C, Carrington MN, Majji S, Yin DE, Jean-Philippe P, Chadwick EG.   +21 more
europepmc   +1 more source